Cureus Case Report: Anti-IgLON5 Disease Masquerading as Cocaine-Induced Disorder
Anti-IgLON5 disease presented as a cocaine-induced hyperkinetic movement disorder in a 43-year-old man, Cureus reported, masking a rare neurodegenerative tauopathy behind acute substance exposure.
-
Key Clinical Takeaways:
- Anti-IgLON5 disease shares clinical features with multiple system atrophy, including sleep dysfunction, bulbar symptoms, and movement disorders.
- Cocaine exposure can trigger or exacerbate hyperkinetic movements, complicating diagnoses when underlying autoimmune disorders go unrecognized.
- Paired serum and cerebrospinal fluid antibody testing remains vital because antibody results can occasionally be discordant between compartments.
According to a report by Cureus, the 2014 identification of anti-IgLON5 disease involved a group of individuals exhibiting a unique sleep condition alongside antibodies targeting IgLON5, which is a neuronal cell adhesion molecule. The disorder sits between autoimmune and neurodegenerative disease, demonstrating a tauopathy predominantly involving the hypothalamus and brainstem tegmentum.
These patients possess a unique autoantibody and show a significant link to the HLA-DRB1*10:01 and HLA-DQB1*05:01 human leukocyte antigen alleles. The clinical phenotype includes sleep dysfunction, movement disorders, bulbar symptoms, cognitive impairment, autonomic dysfunction, and brainstem manifestations, overlapping substantially with multiple system atrophy.
Because it is linked to myoclonus, tics, dystonia, stereotypies, chorea, akathisia, and choreoathetosis, cocaine is acknowledged as a trigger for hyperkinetic movement disorders. If a person with an undiagnosed case of anti-IgLON5 disease arrives following cocaine consumption, the drug use provides a convenient justification for the symptoms, potentially causing clinicians to halt their investigation before identifying the primary condition.
A systematic review covering 285 documented cases found that 76.5% of patients experienced sleep issues, 61.4% suffered from bulbar dysfunction, and 56.1% exhibited movement disorders. In the initial clinical study, 14 of the 16 individuals who provided paired samples tested positive for IgLON5 antibodies in both the serum and the cerebrospinal fluid, whereas the remaining two individuals showed antibody presence solely in the serum.
Following a positive serum IgLON5 antibody result at 1:1920 on readmission, lumbar puncture confirmed cerebrospinal fluid positivity at 1:128. Treatment with intravenous methylprednisolone followed by a five-day intravenous immunoglobulin course led to the resolution of movement and sleep symptoms.
By the outpatient neuroimmunology follow-up, movement, speech, and cognitive symptoms were in remission, with maintenance intravenous immunoglobulin scheduled every four weeks.
Cureus, the journal publishing this case report, began as PeerEMed in 2009 and adopted its current name in December 2012 under founding editors-in-chief John R. Adler of Stanford University and Alexander Muacevic of LMU Munich.
It uses pre-publication peer review alongside a post-publication Scholarly Impact Quotient system and became part of the Springer Nature group in December 2022. The journal is indexed in PubMed Central and Google Scholar, though Clarivate removed it from the Master Journal List in 2025, ending its Web of Science coverage.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.